188 related articles for article (PubMed ID: 26057002)
1. WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients.
Liu D; Wu C; Jiao Y; Hou L; Lu D; Zheng H; Chen C; Qian J; Fei K; Su B
Sci Rep; 2015 Jun; 5():11114. PubMed ID: 26057002
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer.
Liu D; Cao Z; Xu W; Lin G; Zhou X; Ding X; Wang N; Wu C; Su B
Biomed Pharmacother; 2019 Sep; 117():109185. PubMed ID: 31387179
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ
J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease.
Choi MK; Hong JY; Chang W; Kim M; Kim S; Jung HA; Lee SJ; Park S; Chung MP; Sun JM; Park K; Ahn MJ; Ahn JS
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1217-25. PubMed ID: 24696125
[TBL] [Abstract][Full Text] [Related]
5. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.
Mlak R; Krawczyk P; Ciesielka M; Kozioł P; Homa I; Powrózek T; Prendecka M; Milanowski J; Małecka-Massalska T
Clin Transl Oncol; 2016 Sep; 18(9):915-24. PubMed ID: 26650486
[TBL] [Abstract][Full Text] [Related]
6. PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
Papadaki C; Sfakianaki M; Lagoudaki E; Giagkas G; Ioannidis G; Trypaki M; Tsakalaki E; Voutsina A; Koutsopoulos A; Mavroudis D; Georgoulias V; Souglakos J
Br J Cancer; 2014 Oct; 111(9):1757-64. PubMed ID: 25233397
[TBL] [Abstract][Full Text] [Related]
7. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Xu H; Zhang Q; Liang L; Li J; Liu Z; Li W; Yang L; Yang G; Xu F; Ying J; Zhang S; Wang Y
Cancer Med; 2020 May; 9(10):3328-3336. PubMed ID: 32168429
[TBL] [Abstract][Full Text] [Related]
8. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Joerger M; deJong D; Burylo A; Burgers JA; Baas P; Huitema AD; Beijnen JH; Schellens JH
Lung Cancer; 2011 Nov; 74(2):310-7. PubMed ID: 21529986
[TBL] [Abstract][Full Text] [Related]
9. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
Joerger M; Burgers SA; Baas P; Smit EF; Haitjema TJ; Bard MP; Doodeman VD; Smits PH; Vincent A; Huitema AD; Beijnen JH; Schellens JH
Cancer; 2012 May; 118(9):2466-75. PubMed ID: 22031394
[TBL] [Abstract][Full Text] [Related]
10. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
[TBL] [Abstract][Full Text] [Related]
11. The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum.
Xie FJ; Zhao P; Kou JY; Hong W; Fu L; Hu L; Hong D; Su D; Gao Y; Zhang YP
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1443-8. PubMed ID: 22371153
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.
Moro-Sibilot D; Smit E; de Castro Carpeño J; Lesniewski-Kmak K; Aerts J; Villatoro R; Kraaij K; Nacerddine K; Dyachkova Y; Smith KT; Taipale K; Girvan AC; Visseren-Grul C; Schnabel PA
Lung Cancer; 2015 May; 88(2):215-22. PubMed ID: 25748103
[TBL] [Abstract][Full Text] [Related]
13. Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
Cheng H; Qin Q; Sun X; Li F; Sun N; Cheng L; Lu Z; Chen B
Technol Cancer Res Treat; 2013 Oct; 12(5):473-82. PubMed ID: 23617284
[TBL] [Abstract][Full Text] [Related]
14. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.
Tibaldi C; Giovannetti E; Tiseo M; Leon LG; D'Incecco A; Loosekoot N; Bartolotti M; Honeywell R; Cappuzzo F; Ardizzoni A; Peters GJ
Ann Oncol; 2012 Mar; 23(3):670-677. PubMed ID: 21652582
[TBL] [Abstract][Full Text] [Related]
15. XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.
Zhang T; Sun J; Lv M; Zhang L; Wang X; Ren JC; Wang B
Asian Pac J Cancer Prev; 2013; 14(2):701-5. PubMed ID: 23621222
[TBL] [Abstract][Full Text] [Related]
16. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
Nie X; Cheng G; Ai B; Zhang S
Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer.
Hu W; Fang J; Nie J; Dai L; Zhang J; Chen X; Ma X; Tian G; Wu D; Han S; Han J; Wang Y; Long J
Medicine (Baltimore); 2016 Jul; 95(28):e4183. PubMed ID: 27428214
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.
Mellema WW; Masen-Poos L; Smit EF; Hendriks LE; Aerts JG; Termeer A; Goosens MJ; Smit HJ; van den Heuvel MM; van der Wekken AJ; Herder GJ; Krouwels FH; Stigt JA; van den Borne BE; Haitjema TJ; Staal-Van den Brekel AJ; van Heemst RC; Pouw E; Dingemans AM
Lung Cancer; 2015 Nov; 90(2):249-54. PubMed ID: 26415993
[TBL] [Abstract][Full Text] [Related]
19. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Liu L; Zhou F; Ren S; Chen X; Li X; Li W; Zhou C
Asia Pac J Clin Oncol; 2016 Jun; 12(2):e339-46. PubMed ID: 25131817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
